Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Objective: We studied whether the use of hydroxychloroquine (HCQ) for COVID‐19 resulted in supply shortages for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods: We used US claims data (IQVIA PHARMETRICS® Plus for Academics [PHARMETRICS]) and hospital electroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercadé‐Besora, N, Guo, Y, Du, M, Li, X, Ramírez‐Anguita, JM, Moreno, A, Valente, A, Villalobos, F, Cheng, IL, Carrasco‐Ribelles, LA, van Swieten, MMH, Merkelbach, M, Magoya, M, Lasalvia, P, Pericàs‐Pulido, P, Berg, P, Bosco‐Lévy, P, Lillini, R, Ribeiro, R, Bagga, TK, Ramella, V, Khalid, S, Mayer, MA, Leis, A, Jödicke, AM, Burn, E, Prieto‐Alhambra, D, Català, M, Prats‐Uribe, A
Formato: Journal article
Lenguaje:English
Publicado: Wiley 2024

Ejemplares similares